Skip to main content
Industry News
Akebia files NDA for anemia drug vadadustat

A new drug application was filed by Akebia Therapeutics with the FDA for vadadustat, a drug to treat anemia in adult patients not on dialysis and those that are dialysis-dependent. The FDA's review of data from its non-dialysis and dialysis trials over the next 60 days will establish if the NDA is acceptable for review, according to Akebia CEO John Butler.

Full Story: